<DOC>
	<DOCNO>NCT03085641</DOCNO>
	<brief_summary>To investigate whether nHFT effective treatment patient Chronic Heart Failure ( CHF ) central sleep apnea ( CSA ) . This study prospective one arm uncontrolled intervention pilot study investigate 4 week nHFT home 10 patient CHF CSA .</brief_summary>
	<brief_title>Treatment Central Sleep Apnoea Patients With Heart Failure With Nasal High Flow Therapy ( nHFT )</brief_title>
	<detailed_description>Study population : 10 CHF patient Left Ventricular Injection Fraction ( LVEF ) &lt; 45 % CSA/Cheyne Stokes Respiration ( CSR ) ( apnoea/hypopnea index ( AHI ) &gt; 15/hour ) ; least 50 % total number event central character include . Patients diseases influence respiratory system negatively sleep i.e . chronic obstructive pulmonary disease ( COPD Global Initiative Obstructive Lung Diseases ( GOLD ) class 3 4 ) , neuromuscular disease thorax cage deformity , well patient CHF CSA use another form treatment CSA time inclusion , exclude . Intervention : nHFT titrate first titration night use home night 4 week consecutively . Main study parameters/endpoints : 1 . To investigate effect nHFT without oxygen reduce apnoea/hypopnoea index sleep 4 week use nHFT . 2 . To investigate improvement oxygen desaturation index , sleep quality sleepiness , physical condition , leave ventricular ejection fraction ( LVEF ) , heart beat variability ( HRV ) , N-terminal natriuretic peptide ( NTproBNP ) 4 week use nHFT . 3 . Physiological condition ; work breathe respiratory drive measure mouth-throat pressure .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Apnea</mesh_term>
	<mesh_term>Sleep Apnea Syndromes</mesh_term>
	<mesh_term>Cheyne-Stokes Respiration</mesh_term>
	<mesh_term>Sleep Apnea , Central</mesh_term>
	<criteria>1 . Moderate severe CSA/CSR ( AHI &gt; 15 ) , CSA define least 50 % apnoeas central apnoeas 2 . Heart failure reduce ejection fraction , define LVEF &lt; 45 % predict 1 . Other disease affect respiration sleep ( COPD GOLD 3 4 , neuromuscular disorder , thorax cage deformity ) 2 . At moment inclusion , patient therapy treat CSA , continuous positive airway pressure ( CPAP ) , oxygen , bilevel intermittent positive airway pressure ( BiPAP ) acetazolamide .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>High flow oxygen therapy</keyword>
</DOC>